ProfileGDS5678 / 1418092_s_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 73% 74% 74% 73% 74% 74% 74% 77% 74% 73% 74% 73% 73% 74% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.7295573
GSM967853U87-EV human glioblastoma xenograft - Control 24.7944474
GSM967854U87-EV human glioblastoma xenograft - Control 34.7927674
GSM967855U87-EV human glioblastoma xenograft - Control 44.7699273
GSM967856U87-EV human glioblastoma xenograft - Control 54.7843474
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.7956974
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.7922374
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.1783477
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.7885274
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.7945473
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.7885274
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.7776273
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.7522473
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.7941974